Furthermore, [177Lu]Lu-trastuzumab has been evaluated in a preliminary clinical study carried out in 8 cancer patients with HER2-positive metastatic BC, showing the preferential localization of the tracer in tumor lesions that warrant further studies for the evaluation of its therapeutic potential (43). The gene discussed is ERBB2; the disease is neoplasm.